Endocrine Society Learning Center

Log-in / Create Account

Session Information

ENDO 2010 Annual Meeting - Includes 5 Complimentary Sessions

Click here to go to the previous page

Novel Therapy for Medullary Thyroid Carcinoma

Track : CLINICAL

Program Code: S08-1

Date: Saturday, June 19, 2010

Time: 9:30 AM to 10:00 AM EST

Location: 31ABC

SPEAKER :

Marcia S Brose, MD PhD, Univ of Pennsylvania, Philadelphia, PA
Disclosure: Principal Investigator, Bayer, Inc., Novartis Pharmaceuticals; Speaker, Bayer, Inc.; Study Investigator, Exelixis, Daichi-Sanyo; Research Funding, Onyx.

Marcia S. Brose, MD, PhD is an assistant professor at the University Of Pennsylvania School Of Medicine, in the departments of Medicine, division of Hematology/Oncology, and Otorhinolaryngology: Head and Neck Surgery, where she is currently the Director of the Head and Neck Clinical Research and Director of the Thyroid Cancer Therapeutics Program. She received her Medical Degree from Cornell University Medical College, and her PhD from the Rockefeller University in New York City. Following her graduation, she moved to the Hospital of the University of Pennsylvania where she completed her specialty training in Internal Medicine, and Hematology and Oncology. Trained in genetics, Dr. Brose then pursued additional post-doctoral training in the field of cancer genetics in the laboratory of Barbara Weber MD. At the time of her appointment as a faculty member, Dr. Brose chose to focus on the genetics of head and neck cancers, and in particular, thyroid cancer. Dr. Brose�s current research interests include the identification of novel treatments for advanced thyroid cancer. She is currently running her own program in thyroid cancer therapeutics at the Abramson Cancer Center of the University of Pennsylvania, and is the PI of four active clinical phase I-II clinical trials. She has also been appointed a co-PI of the pivotal international multi-institutional Phase III trial of sorafenib for patients with iodine refractory differentiated thyroid cancer. Her publication on her Phase II trial of sorafenib in advanced thyroid cancer has been described as creating a paradigm shift in the care of these patients. Dr. Brose is the director of the Head and Neck Research Program for the Department of the University of Pennsylvania, and Co-PI of the Head and Neck Tissue bank. She has a strong interest in translational research, and runs her own lab studying bio-samples from patients on her clinical trials. Dr. Brose is a member of the American Association of Cancer Research, American Head and Neck Society, and American Society of Clinical Oncology. She is the recipient of the several prestigious awards including the Damon Runyon Clinical Investigator award, and the General Motors Cancer Research Foundation Research Scholar Award.

Audio Synchronized to PowerPoint

(Code: S08-1)

This session is a part of:

The COMPLETE Bundle: Full Regular ENDO Session Library + Career Development Resources + Thyroid Ultrasonography (Online Access & DVD-ROM)

Full Regular ENDO Session Library (Online Access & DVD-ROM)